These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38849845)

  • 1. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
    Zuckermann M; He C; Andrews J; Bagchi A; Sloan-Henry R; Bianski B; Xie J; Wang Y; Twarog N; Onar-Thomas A; Ernst KJ; Yang L; Li Y; Zhu X; Ocasio JK; Budd KM; Dalton J; Li X; Chepyala D; Zhang J; Xu K; Hover L; Roach JT; Chan KC; Hofmann N; McKinnon PJ; Pfister SM; Shelat AA; Rankovic Z; Freeman BB; Chiang J; Jones DTW; Tinkle CL; Baker SJ
    Mol Cancer; 2024 Jun; 23(1):123. PubMed ID: 38849845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
    International Cancer Genome Consortium PedBrain Tumor Project
    Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
    Ramesh S; Cifci A; Javeri S; Minne RL; Longhurst CA; Nickel KP; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1379-1390. PubMed ID: 37979706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.
    Kim JS; Kim MY; Hong S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
    Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
    Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
    Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
    J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity.
    Gorodezki D; Chiang J; Viaene AN; Sievers P; Schmid S; Holzer U; Paulsen F; Schuhmann MU; Witt O; Schittenhelm J; Ebinger M
    Acta Neuropathol Commun; 2024 Jun; 12(1):101. PubMed ID: 38902810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
    Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
    Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
    Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
    Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
    Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.
    Navis AC; van Lith SA; van Duijnhoven SM; de Pooter M; Yetkin-Arik B; Wesseling P; Hendriks WJ; Venselaar H; Timmer M; van Cleef P; van Bergen En Henegouwen P; Best MG; Wurdinger TD; Tops BB; Leenders WP
    Acta Neuropathol; 2015 Jul; 130(1):131-44. PubMed ID: 25862637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
    Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
    PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.